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IntroductIon
Innate lymphoid cells (ILCs) are mucosal effector cells that 
are derived from common lymphoid progenitors (CLPs). 
They are embedded at environmental interfaces, where they 
can respond rapidly and directly in an antigen-independent 
manner to a wide array of insults. Subsets of ILCs—groups 
1, 2, and 3—mirror the adaptive CD4+ T helper lymphocyte 
lineages Th1, Th2, and Th17, respectively, in regard to their 
transcriptional governance and cytokine production (Klose 
and Artis, 2016; background on ILC reviewed in Morita et al., 
2016). Group 2 ILCs (ILC2s) require GATA3 (Hoyler et al., 
2012; Mjösberg et al., 2012) and produce abundant quantities 
of IL-5, IL-13, and/or IL-9 and, under certain circumstances, 
IL-4, similar to CD4+ Th2 cells (Moro et al., 2010; Neill et 
al., 2010; Price et al., 2010; Wilhelm et al., 2011; Doherty et 
al., 2013). Known activators of ILC2s include IL-33, IL-25, 
thymic stromal lymphopoietin (TSLP), TNF family member 
TL1A, and lipid mediators such as prostaglandin D2 and leu-
kotriene D4 (Moro et al., 2010; Neill et al., 2010; Halim et al., 
2012; Doherty et al., 2013; Xue et al., 2014; Yu et al., 2014). 
ILC2s have been implicated directly in the pathogenesis of 
inflammatory diseases in animal models or humans including 
asthma (Bartemes et al., 2012, 2014; Halim et al., 2012; Chris-
tianson et al., 2015), atopic dermatitis (Kim et al., 2013; Salimi 
et al., 2013), chronic rhinosinusitis (Mjösberg et al., 2011; 
Shaw et al., 2013), viral infection (Chang et al., 2011; Jack-
son et al., 2014), and helminth infection (Moro et al., 2010; 
Neill et al., 2010; Price et al., 2010). Additionally, ILC2s regu-
late tissue homeostasis, including epithelial repair (Monticelli 
et al., 2011, 2015) and healthy adipose tissue maintenance 
(Molofsky et al., 2013; Brestoff et al., 2015; Lee et al., 2015).
Our understanding of ILC2 egress from developmental 
sites such as the bone marrow and subsequent trafficking to 
tissues is highly limited. The establishment of ILC2 niches in 
the periphery occurs in the perinatal period. For instance, 
seeding of the lungs occurs within the first 2 wk of life in an 
IL-33–dependent manner (de Kleer et al., 2016; Saluzzo et 
al., 2017; Steer et al., 2017). After colonization, maintenance 
of ILC2 populations in mucosal tissues is thought to occur by 
multiple mechanisms. Intrinsically, ILC2s are long lived in the 
tissue (Nussbaum et al., 2013). Under steady-state conditions, 
data suggest that ILC2s are replenished from ILC2 or ILC2 
lineage progenitor cells that are in situ within these peripheral 
tissues (Gasteiger et al., 2015; O’Sullivan et al., 2016). How-
ever, in the context of protracted type 2 inflammation such 
as Nippostrongylus brasiliensis infection, ILC2s are in part re-
seeded hematogenously, likely from sources such as the bone 
marrow (Gasteiger et al., 2015). Moreover, myeloablation and 
reconstitution with donor bone marrow leads to a significant 
accumulation of donor ILC2s in classically ILC2-rich sites, 
including the colon and skin in humans (Vély et al., 2016). 
Collectively, these data implicate both peripheral and cen-
tral mechanisms in the maintenance of ILC2 frequencies in 
peripheral tissues, particularly in the context of initial tissue 
seeding and disrupted tissue homeostasis.
Group 2 innate lymphoid cells (ILc2s) are effector cells within the mucosa and key participants in type 2 immune responses in 
the context of allergic inflammation and infection. ILc2s develop in the bone marrow from common lymphoid progenitor cells, 
but little is known about how ILc2s egress from the bone marrow for hematogenous trafficking. In this study, we identified a 
critical role for IL-33, a hallmark peripheral ILc2-activating cytokine, in promoting the egress of ILc2 lineage cells from the 
bone marrow. Mice lacking IL-33 signaling had normal development of ILc2s but retained significantly more ILc2 progenitors 
in the bone marrow via augmented expression of cXcr4. Intravenous injection of IL-33 or pulmonary fungal allergen challenge 
mobilized ILc2 progenitors to exit the bone marrow. Finally, IL-33 enhanced ILc2 trafficking to the lungs in a parabiosis mouse 
model of tissue disruption and repopulation. collectively, these data demonstrate that IL-33 plays a critical role in promoting 
ILc2 egress from the bone marrow.
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Development of ILC2s in the bone marrow has been 
the subject of intense interest. Thematically, our understand-
ing of ILC2 development has focused largely on critical tran-
scriptional regulators such as Bcl11b and ETS1 (Walker et al., 
2015; Yu et al., 2015; Zook et al., 2016; and reviewed in Zook 
and Kee, 2016). However, the role of extracellular signals in 
ILC2 development remains more poorly defined. Mice defi-
cient in the Il7r or Il2r have markedly reduced numbers of 
ILC2s, suggesting a critical role for these cytokines in ILC2 
development and/or homeostasis (Moro et al., 2010; Wong et 
al., 2012). An in vitro system for the differentiation of CLPs 
to ILC2s requires IL-7, Notch ligand, and IL-33 (Wong et 
al., 2012; Xu et al., 2015). IL-33 is a hallmark activator of 
ILC2s in peripheral tissues, and the most mature ILC2 lineage 
cell in the bone marrow, referred to as the ILC2 progeni-
tor (ILC2P), expresses the IL-33 receptor ST2 (Hoyler et al., 
2012; Spooner et al., 2013). However, a role for IL-33 in ILC2 
lineage development or trafficking in vivo remains unknown.
We sought to understand the role of IL-33, a quintes-
sential peripheral activator of ILC2s, in bone marrow ILC2 
lineage development and trafficking. Il33−/− and St2−/− mice 
had significantly increased numbers of ILC2Ps in the bone 
marrow and reduced numbers of ILC2s in peripheral tissues 
compared with WT mice. Lack of IL-33 signaling precipi-
tated critical changes in the chemokine receptor profile of 
ILC2Ps. Notably, ILC2Ps in St2−/− mice expressed higher 
levels of CXCR4, which stimulated the retention of ILC2Ps 
in the bone marrow. Finally, sublethal radiation exposure in 
parabiotic mice established a key role for IL-33–responsive 
hematogenous trafficking of ILC2s in the setting of disrupted 
tissue homeostasis. Collectively, these data implicate IL-33 as a 
key driver of bone marrow ILC2 lineage cell egress.
resuLts
deficiency in IL-33 signaling promotes the accumulation of 
ILc2Ps in the bone marrow
IL-33 signaling via its receptor ST2 is a central pathway for 
the activation of ILC2 effector functions in peripheral tis-
sues. Moreover, IL-33 has been used in vitro to stimulate the 
differentiation of ILC2s from CLPs (Wong et al., 2012; Xu 
et al., 2015). We hypothesized that IL-33 promotes the de-
velopment of ILC2s in vivo. Accordingly, we assayed for the 
number of ILC2Ps in the bone marrow of naive BALB/c 
WT, Il33−/−, and St2−/− mice. ILC2Ps and peripheral ILC2s 
were defined as viable cells that were CD45+ Lin− IL-25R+ 
CD25+ CD127+ (Fig. 1 A). WT, Il33−/−, and St2−/− mice had 
similar numbers of total cells in the bone marrow (Fig. 1 B), 
but unexpectedly, we identified a significant increase in the 
frequency and total number of ILC2Ps in Il33−/− and St2−/− 
mice compared with WT mice (Fig. 1, A, C, and D). A similar 
increase in the total number of bone marrow ILC2Ps was 
observed in Il33−/− mice on a C57BL/6 background, indi-
cating that this phenotype was independent of host genetic 
background (Fig.  1  E). We next characterized the number 
of ILC2s in peripheral tissues. We focused on ILC2-rich tis-
sues, specifically the lungs, skin, and mesenteric lymph nodes 
(mLNs). In contrast to our result in the bone marrow, we 
found a significant decrease in the frequency and total num-
ber of ILC2s in the lungs and skin of Il33−/− and St2−/− mice 
compared with WT mice, and a significant decrease in the 
frequency and total number of ILC2s in the mLNs of St2−/− 
mice compared with WT mice (Fig. 2). This phenotype of 
accumulation in the bone marrow in Il33−/− and St2−/− mice 
was unique to ILC2s among major ST2-expressing cell types, 
as eosinophil, basophil, and mast cell lineages did not ex-
hibit increased frequency in the bone marrow of St2−/− mice 
(Fig. S1 A). Fewer eosinophils were recovered from the lungs 
and skin of St2−/− mice, likely secondary to the reduction 
of ILC2s in these tissues (Fig. S1, B and C; Nussbaum et al., 
2013). These data suggested that IL-33 might affect ILC2P 
egress from the bone marrow.
In addition to IL-33, TSLP is a potent activator of 
ILC2s. However, these two cytokines act via distinct cellular 
pathways. IL-33 binds to ST2 to induce MyD88 activation 
and NF-κB translocation to the nucleus, whereas TSLP binds 
to a heterodimer of the TSL PR and IL-7Rα and activates 
STAT5 (reviewed in Bartemes and Kita, 2012). We assessed 
whether the effects on ILC2P/ILC2 frequency were unique 
to IL-33 signaling or were part of a broader network of 
ILC2-activating cytokines that functioned redundantly. We 
measured the number of ILC2Ps in the bone marrow and 
ILC2s in the lungs of WT and Tslpr−/− mice. In contrast to 
mice lacking IL-33 signaling, the loss of TSL PR signaling re-
duced the frequency and total number of ILC2Ps in the bone 
marrow (Fig. S2, A–D) and ILC2s in the lungs (Fig. S2, E–H) 
compared with WT mice. These data indicate that IL-33 acts 
distinctly from other ILC2-activating cytokines in regulating 
bone marrow ILC2P frequency and that TSLP may instead 
play an important role in ILC2 development.
IL-33 deficiency does not appreciably alter the hallmark 
functional capacities of ILc2Ps
We considered whether the increase in ILC2P frequency 
might be a compensatory effect for reduced proliferative po-
tential or cytokine-producing capacity of ILC2Ps in Il33−/− 
and St2−/− mice. ILC2Ps from the bone marrow of WT and 
Il33−/− mice were enriched by magnetic selection for lineage 
negative cells, purified by FACS, and cultured with IL-2 alone 
or IL-2 plus IL-33. ILC2Ps from Il33−/− mice have developed 
in the absence of IL-33 but have an intact St2 gene locus 
and are poised to respond to IL-33. Thus, we were able to 
consider the developmental role of IL-33 on the proliferative 
capacity and cytokine expression of ILC2Ps.
Before culture, we stained ILC2Ps with CellTrace Violet 
to measure proliferation. After 5 d of in vitro culture, we har-
vested ILC2Ps for flow cytometric analysis of CellTrace Vio-
let dye dilution (Fig. 3 A). For both WT and Il33−/− ILC2Ps, 
IL-2 alone did not induce proliferation. IL-2 and IL-33 in 
combination induced robust proliferation as measured by se-
rial dye dilution in both WT and Il33−/− ILC2Ps. Importantly, 
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no difference was observed in the proliferation between WT 
and Il33−/− ILC2Ps in response to IL-33. Similarly, the prolif-
eration index was identical between WT and Il33−/− ILC2Ps 
(Fig. 3 B). Finally, we counted the number of cells in each 
well after 5 d of culture (Fig. 3 C). IL-33 in combination with 
IL-2 induced a significant increase in the total number of WT 
and Il33−/− ILC2Ps compared with IL-2 alone. However, no 
difference was observed in the number of ILC2Ps between 
IL-33–stimulated WT and Il33−/− cultures.
We also collected supernatants from these ILC2P cul-
tures to assess the cytokine-expressing capacity of WT and 
Il33−/− ILC2Ps. IL-2 alone did not induce IL-5 or IL-13 pro-
duction from either WT or Il33−/− ILC2Ps. Stimulation with 
IL-2 and IL-33 in combination significantly induced IL-5 and 
IL-13 expression in both strains of ILC2Ps. A slight (∼10%) 
but reproducible difference in IL-5 expression was detected, 
with WT ILC2Ps producing marginally higher quantities of 
IL-5 than Il33−/− ILC2Ps (Fig. 3 D). No significant difference 
was observed in the expression of IL-13 between WT and 
Il33−/− ILC2Ps (Fig.  3  E). Collectively, these data indicate 
that ILC2Ps that develop in the absence of IL-33 signaling 
are functionally similar to WT ILC2Ps in their capacity to 
proliferate and express IL-5 and IL-13.
Lack of IL-33 signaling does not alter the rate of de novo 
ILc2P generation in the bone marrow
We also considered whether the difference in ILC2P num-
bers in the bone marrow of mice competent for or lack-
ing IL-33 signaling could be explained by a different rate of 
generation of these cells from precursors. First, we looked 
at the abundance of upstream progenitor cells, specifically 
lymphoid-primed multipotent progenitors (LMPPs), CLPs, 
common helper innate lymphoid progenitors (CHI LPs), and 
innate lymphoid cell progenitors (ILCPs), in the bone marrow 
of WT and St2−/− mice (gating strategy detailed in Fig. S3 and 
Table S3). LMPPs and CLPs can differentiate into T, B, NK, 
and all ILCs with varying efficiencies (Ghaedi et al., 2016). 
CHI LPs are restricted to differentiate into ILC1s, ILC2s, and 
ILC3s as well as lymphoid tissue inducer cells (Klose et al., 
2014). ILCPs only differentiate into ILC1s, ILC2s, and ILC3s 
(Constantinides et al., 2014). We did not observe any signif-
icant differences in the total number of LMPP, CLP, CHI LP, 
or ILCP populations between WT and St2−/− mice (Fig. 3, 
F–I). Therefore, the first divergence in cell frequency in the 
ILC2 developmental lineage that we observed occurred at 
the mature ILC2P stage.
To assess the rate of ILC2P lymphopoiesis, we injected 
WT and St2−/− mice daily with BrdU for 5 d and harvested 
their bone marrow 24 h after the final injection to evaluate 
for BrdU incorporation in ILC2Ps (Fig.  3  J). BrdU incor-
poration is a property of lymphopoiesis and marks de novo 
generated cells in the bone marrow, allowing us to assess 
the rate of ILC2P development. A small fraction of BrdU+ 
ILC2Ps was measured in both WT and St2−/− mice. However, 
no significant difference in the number of BrdU+ ILC2Ps was 
observed (Fig. 3 K). Because the 5-d time course may capture 
Figure 1. deficiency in IL-33 signaling 
leads to an accumulation of ILc2Ps in the 
bone marrow. Adult naive WT BALB/c, Il33−/−, 
and St2−/− mice were killed, and bone marrow 
from one tibia and femur was prepared for 
flow cytometric analysis. (A) Gating strategy 
and representative gating of WT, Il33−/−, and 
St2−/− ILC2Ps. ILC2Ps were defined as viable 
CD45+ FSC-Alo SSC-Alo Lin− IL-25R+ CD25+ 
CD127+ cells. (B) The total number of viable 
bone marrow cells. (c) ILC2P frequency among 
live bone marrow cells. (d) The total number 
of ILC2Ps in the bone marrow. (e) The total 
number of ILC2Ps in the bone marrow of WT 
C57BL/6 and Il33−/− mice on a C57BL/6 back-
ground. Data are representative of three in-
dependent experiments (A) or combined from 
two (E, n = 8–9) or three (B-D, n = 10–13) 
independent experiments and displayed as 
the mean ± SEM. **, P < 0.01; ***, P < 0.001 
by one-way ANO VA with Bonferroni posttest 
(B–D) or unpaired t test (E); n.s., not signifi-
cant. Values within flow plots indicate percent 
of the parent population.
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the balance of both cell division and cell death, we repeated 
this assay with a single injection of BrdU and analyzed the 
mice 2  h later. Similar results were obtained, although the 
total number of BrdU+ ILC2Ps was substantially lower, likely 
because of a low rate of ILC2 lymphopoiesis in naive adult 
mice (not depicted). These data suggest that ILC2Ps are being 
generated from precursors at a similar rate in the presence or 
absence of IL-33 signaling. Altogether, these data demonstrate 
that ILC2s develop similarly in the absence of IL-33 but are 
increased in the bone marrow and decreased in the periph-
ery in the absence of IL-33 signaling, suggestive of a role for 
IL-33 in promoting bone marrow egress.
st2 deficiency promotes bone marrow ILc2P accumulation 
in the perinatal period
Initial ILC2 seeding of the lungs occurs within the first 2 wk 
of life in an IL-33–dependent manner, suggesting a poten-
tially critical window in perinatal life for IL-33–dependent 
Figure 2. deficiency in IL-33 signaling decreases the number of ILc2s in peripheral tissues. (A–c) Adult naive WT, Il33−/−, or St2−/− mice were killed, 
and lungs, skin, and mLNs were collected. ILC2 representative gating in the lungs (A), skin (B), and mLNs (C). (d) The total number of viable lung cells (left 
and right lung combined), ILC2 frequency among live lung cells, and the total number of lung ILC2s. (e) The total number of viable skin cells (left and right 
ears combined), ILC2 frequency among live skin cells, and the total number of skin ILC2s. (F) The total number of viable mLN cells per node, ILC2 frequency 
among live mLN cells, and the total number of mLN ILC2s per node. Data are representative of two independent experiments (A–C) or combined from two 
independent experiments (D, n = 7–10; E, n = 5–8; F, n = 6–9) and displayed as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by one-way ANO VA 
with Bonferroni posttest (D–F); n.s., not significant. Values within flow plots indicate percentage of the parent population.
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processes that affect ILC2 development and migration (de 
Kleer et al., 2016; Saluzzo et al., 2017; Steer et al., 2017). We 
measured ILC2Ps/ILC2s in the bone marrow and lungs of 
WT and St2−/− postnatal day 2 (P2) and P15 mice. P2 is be-
fore significant ILC2 seeding of the lungs, and P15 is imme-
diately after peak ILC2 accumulation in the lungs. ILC2Ps/
ILC2s were found at low but comparable levels in the bone 
marrow and lungs of P2 WT and St2−/− mice (Fig. 4, A, B, 
and E). However, ILC2Ps were significantly more abundant 
in the bone marrow of St2−/− P15 mice compared with WT 
mice (Fig.  4, C and F). Concurrently, we detected signifi-
cantly fewer ILC2s in the lungs of St2−/− P15 mice com-
pared with WT mice (Fig. 4, D and F). These data indicate 
the importance of IL-33 signaling in regulating ILC2P/
ILC2 abundance in the bone marrow and lungs as early as 
the first 2 wk of life. Moreover, the progressive accumulation 
of ILC2Ps in the bone marrow in conjunction with reduced 
numbers of ILC2s in the lungs of St2−/− mice during the 
highly migratory perinatal period suggest a potentially crit-
ical role for IL-33–mediated bone marrow egress in initial 
tissue seeding by ILC2s.
Intravenously delivered IL-33 drives the egress of 
ILc2Ps from the bone marrow
Numerous human diseases including asthma and atopic der-
matitis have been associated with increased IL-33 in the plasma 
(Miller, 2011). Moreover, ILC2 accumulation in the lungs of 
neonatal mice is associated with a wave of pulmonary IL-33 
expression (de Kleer et al., 2016; Saluzzo et al., 2017; Steer et 
al., 2017). We hypothesized that increased circulating IL-33 
may precipitate egress of ILC2s from the bone marrow. To 
assess the effect of IL-33 on bone marrow ILC2P egress, we 
intravenously injected recombinant murine IL-33 (rIL-33) or 
vehicle into WT mice and measured the number of ILC2Ps 
in the bone marrow 24 h later. Compared with vehicle treat-
ment, intravenous delivery of rIL-33 significantly and robustly 
reduced the frequency and total number of ILC2Ps in the 
bone marrow (Fig. 5, A, C, and D). There was also a modest 
decrease in the total number of bone marrow cells, suggesting 
that exogenous rIL-33 may be promoting egress of other cell 
types (Fig. 5 B). However, analysis of major cell lineages in 
the bone marrow did not reveal a consistent loss of specific 
cell types other than ILC2Ps with rIL-33 treatment compared 
Figure 3. Wt and IL-33–deficient ILc2Ps are comparably functional and develop at a similar rate. ILC2Ps from the bone marrow of WT and 
Il33−/− mice were enriched by magnetic separation and purified by FACS. Sorted ILC2Ps were stained with the dilution-based proliferation dye CellTrace 
Violet and cultured in supplemented RPMI medium in the presence of IL-2 (10 ng/ml) ± IL-33 (10 ng/ml) for 5 d. (A) Representative CellTrace Violet dilution 
peaks. (B) Proliferation index is a measure derived from CellTrace Violet staining for quantifying the mean number of proliferation events undergone by 
each ILC2P that was initially cultured. (c) Cell counts of ILC2Ps poststimulation. (d and e) IL-5 (D) and IL-13 (E) concentrations in the supernatants as 
measured by ELI SA. Adult naive WT and St2−/− mice were killed, and bone marrow from one tibia and femur was prepared for flow cytometric analysis. (F–I) 
The total number of progenitors in the ILC2 lineage was quantified: LMPPs (F), CLPs (G), CHI LPs (H), and ILCP (I). (J) WT and St2−/− mice were treated daily 
with 1 mg BrdU intraperitoneally for 5 d and harvested 24 h after the final dose. (K) The total number of BrdU+ ILC2Ps in the bone marrow from J. Data are 
combined from two independent experiments (B, n = 9; F–I, n = 8; K, n = 9–10) or representative of two similar experiments (A and C–E, n = 4). Data are 
displayed as the mean ± SEM. *, P < 0.05; ***, P < 0.001 by one-way ANO VA with Bonferroni posttest (C–E) or unpaired t test (B, F–I, K); n.s., not significant.
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with vehicle treatment (Fig. S1 D). Additionally, this IL-33–
dependent egress of ILC2Ps occurred in a dose-dependent 
manner (Fig. 5 E). These data indicate that IL-33 is a potent 
inducer of ILC2P egress from the bone marrow.
ILc2P/ILc2 frequencies in st2−/− mice are established by an 
ILc2P/ILc2 cell-intrinsic mechanism
To dissect the mechanism responsible for IL-33–mediated 
ILCP2 bone marrow egress, we first determined whether the 
frequencies of ILC2Ps/ILC2s were established by an ILC2P/
ILC2 cell-intrinsic or cell-extrinsic mechanism using a 
mixed bone marrow chimera model (Fig. 6 A). Whole bone 
marrow from BALB/c congenic WT (CD45.1+) and St2−/− 
(CD45.2+) mice was mixed in a 1:1 ratio. 10 million total cells 
from this mixture were transplanted into lethally irradiated WT 
(CD45.1+ CD45.2+) mice and allowed to reconstitute for 6 wk. 
In the bone marrow, St2−/− (CD45.2+) ILC2Ps were observed 
at a significantly higher frequency than WT (CD45.1+) ILC2Ps, 
consistent with our observation in germline knockout mice 
(Fig. 6 B). In the lungs, skin, and mLNs, WT (CD45.1+) ILC2s 
were observed at a higher frequency than St2−/− (CD45.2+) 
ILC2s, also consistent with our observation in germline knock-
out mice (Fig. 6, C–E). Next, we injected reconstituted bone 
marrow chimeric mice with 4 µg rIL-33 or vehicle (0.1% BSA 
in PBS) and evaluated the percentage reduction of ILC2Ps 
after 24 h. rIL-33 treatment robustly decreased the number of 
WT ILC2Ps in the bone marrow compared with WT ILC2Ps 
in vehicle-treated mice and St2−/− ILC2Ps in rIL-33–treated 
mice (Fig. 6 F). These data indicate that IL-33 promotes ILC2P 
egress in an ST2-dependent, ILC2P-intrinsic mechanism. In-
terestingly, rIL-33 modestly decreased St2−/− ILC2P numbers 
compared with vehicle treatment, suggesting that an IL-33– 
dependent, ILC2P-extrinsic mechanism may also contribute 
to ILC2P exit from the bone marrow.
Figure 4. IL-33 regulates ILc2/ILc2P fre-
quencies in the bone marrow and lung of 
early postnatal mice. Age-matched pups 
were obtained from timed breeding pairs of 
WT and St2−/− mice. (A–d) Representative 
gating for ILC2s and ILC2Ps in P2 bone mar-
row (A), P2 lungs (B), P15 bone marrow (C), and 
P15 lungs (D). (e) The total number of ILC2Ps 
in the bone marrow and ILC2s in the lungs of 
P2 mice. (F) The total number of ILC2Ps in the 
bone marrow and ILC2s in the lungs of P15 
mice. Data are representative of two (C and 
D) or three (A and B) independent experiments 
or combined from two (F, n = 6–10) or three 
(E, n = 12–15) independent experiments and 
displayed as the mean ± SEM. *, P < 0.05; **, P 
< 0.01 by unpaired t test; n.s., not significant. 
Values within flow plots indicate percentage 
of the parent population.
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IL-33 signaling negatively regulates cXcr4 expression to 
promote ILc2P exit from the bone marrow
Regulation of chemokine receptors is a cell-intrinsic mecha-
nism by which lymphocytes guide their retention in and exit 
from sites of development (Griffith et al., 2014). We deter-
mined the effect of endogenous IL-33 signaling on the chemo-
kine receptor expression pattern of bone marrow ILC2Ps. 
WT and St2−/− ILC2Ps were FACS-purified and screened 
for a panel of chemokine receptor or chemokine-associated 
transcripts known to be expressed by ILC2s and/or CD4+ 
Th2 cells. St2−/− ILC2Ps expressed higher levels of Cx3cr1, 
Ccr7, Ccr9, Cxcr4, and Ptgdr2 and lower levels of Ccl1 than 
WT ILC2Ps (Fig. 7 A). CXCR4 signaling facilitates the re-
tention of developing leukocytes, including neutrophils and B 
cells in the bone marrow (Griffith et al., 2014). Therefore, we 
hypothesized that CXCR4 may be acting similarly to retain 
ILC2Ps in the bone marrow. We first confirmed our Cxcr4 
transcript analysis using Il33−/− ILC2Ps (Fig. 7 B). Next, we 
FACS-purified WT ILC2Ps and cultured them for 24 h with 
IL-2 alone or IL-2 and increasing doses of IL-33. IL-33 neg-
atively regulated CXCR4 expression in a dose-dependent 
manner (Fig. 7, C and D). Moreover, IL-33 treatment of WT 
and Il33−/− ILC2Ps but not St2−/− ILC2Ps similarly decreased 
CXCR4 expression, demonstrating the ST2 specificity of 
IL-33–mediated CXCR4 attenuation (Fig. 7 E).
We previously demonstrated that increased circulating 
IL-33 promoted the egress of ILC2Ps from the bone mar-
row (Fig.  5). To determine whether this IL-33–mediated 
ILC2P egress correlated with decreased CXCR4 expression, 
we treated WT mice intravenously with exogenous rIL-33 
(4 µg) and measured CXCR4 expression on ILC2Ps after 
24 h. Compared with vehicle treatment, rIL-33 significantly 
decreased the expression of CXCR4 as well as the percent-
age of CXCR4+ ILC2Ps (Fig. 7 F). This effect was consis-
tently identified with high doses of rIL-33 (4 µg) but not 
lower doses (1 µg, not depicted). This may be explained by 
egress dynamics, wherein ILC2Ps that have down-regulated 
CXCR4 exit the bone marrow and are no longer included in 
the pool of ILC2Ps that we analyzed. Higher doses of rIL-33 
may induce a stronger down-regulation of CXCR4, allow-
ing us to overcome this limitation and consistently identify 
differences. Alternatively, enhanced rIL-33 loads above basal 
levels may affect additional pathways beyond CXCR4 that 
influence ILC2P egress. Endogenous and exogenous IL-33 
signaling did not alter CCR3 expression on other ST2+ 
populations including eosinophils, basophils, and mast cell 
bone marrow lineage cells and did not alter CXCR4 ex-
pression on known CXCR4+ cells with the exception of 
neutrophils, in which CXCR4 was reduced with rIL-33 
treatment (Fig. S1, E and F).
To determine whether elevated CXCR4 expression 
in St2−/− ILC2Ps was acting to retain ILC2Ps in the bone 
marrow, we treated WT and St2−/− mice with AMD3100, 
a selective and potent antagonist of CXCR4 (Fig.  7  G). 
Treatment of St2−/− mice with AMD3100 significantly re-
duced the number of ILC2Ps in the bone marrow compared 
with vehicle-treated St2−/− mice (Fig.  7  H). This decrease 
accounted for approximately half of the difference in the 
number of ILC2Ps between vehicle-treated WT and St2−/− 
mice. AMD3100 did not significantly reduce the number of 
ILC2Ps in WT mice. WT ILC2Ps may be less dependent on 
Figure 5. direct intravenous administration of IL-33 decreases ILc2P 
frequency in the bone marrow. Adult naive WT mice were treated intra-
venously with rIL-33 or vehicle (0.1% BSA in PBS), and bone marrow was 
harvested 24 h later for flow cytometric analysis. (A) Representative gating 
for bone marrow ILC2Ps from mice treated with vehicle or 1 µg rIL-33. (B) 
The total number of viable bone marrow cells. (c) ILC2P frequency among 
live bone marrow cells. (d) The total number of ILC2Ps in the bone marrow. 
(e) The total number of ILC2Ps in the bone marrow of mice treated with 
vehicle or 0.25, 1, or 4 µg rIL-33 for 24 h. Data are combined from two 
independent experiments (B–D, n = 8–10; E, n = 7) or representative of two 
independent experiments (A) and are displayed as the mean ± SEM. *, P < 
0.05; **, P < 0.01; ***, P < 0.001 by unpaired t test (B–D) or one-way ANO VA 
with Bonferroni posttest (E). Values within flow plots indicate percentage 
of the parent population.
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CXCR4 signaling for bone marrow retention considering 
their lower level of Cxcr4 expression (Fig. 7, A and B). There-
fore, short-course inhibition of CXCR4 with AMD3100 in 
WT mice may be insufficient to induce a difference in the 
bone marrow retention of ILC2Ps. Collectively, these data 
suggest that endogenous IL-33 signaling attenuates CXCR4 
expression on ILC2Ps, allowing for their efficient egress from 
the bone marrow. Furthermore, inhibition of CXCR4 sig-
nificantly, but only partially, reduced the number of ILC2Ps in 
the bone marrow, highlighting that IL-33 is likely regulating 
multiple pathways that may collaborate to promote egress.
We next considered whether CXCR4 signaling was 
regulating ILC2P exit from the bone marrow in early postna-
tal mice. ILC2Ps from P2 WT and St2−/− mice, representing a 
time point before significant ILC2 migration, had comparable 
expression of CXCR4 and a similar frequency of CXCR4+ 
ILC2Ps (Fig. 7 I). By P15, representing a time point imme-
diately after ILC2 migration, St2−/− ILC2Ps displayed signifi-
cantly increased expression of CXCR4 compared with WT 
ILC2Ps (Fig. 7 J). Similarly, there was an increased frequency 
of CXCR4+ ILC2Ps in P15 St2−/− mice compared with 
WT mice (Fig. 7 J). We validated these results in P15 Il33−/− 
Figure 6. tissue frequencies of ILc2s/ILc2Ps are established by a cell-intrinsic, st2-dependent mechanism. 6-wk-old heterozygous CD45.1+ 
CD45.2+ WT mice were lethally irradiated and reconstituted with 10 million cells of a 1:1 mixture of CD45.1+ WT and CD45.2+ St2−/− total bone marrow cells. 
(A) Experimental design. (B) ILC2P representative gating and pooled analyses of WT and St2−/−-derived ILC2Ps displayed as frequencies of donor-derived 
ILC2Ps. (c–e) ILC2 representative gating and pooled analyses of WT and St2−/−-derived ILC2s displayed as frequencies of donor-derived ILC2s in the lungs 
(C), skin (D), and mLNs (E). (F) Bone marrow chimeric mice were treated intravenously with 4 µg rIL-33 or vehicle (0.1% BSA in PBS), and cells were harvested 
24 h later. ILC2P total cell numbers in the vehicle-treated mice are normalized to 100% for each genotype (WT or St2−/−). ILC2Ps in the rIL-33–treated mice 
are displayed as the percentage of vehicle-treated mice within their respective genotype. Data are combined from two (D, n = 7; E, n = 5; F, n = 6) or three 
(B and C, n = 13) independent experiments and displayed as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by unpaired t test (B–E) or one-way 
ANO VA with Bonferroni posttest (F). Values within flow plots indicate percentage of the parent population.
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Figure 7. IL-33 negatively regulates cXcr4 to promote efficient egress of ILc2Ps. (A) ILC2Ps were magnetically enriched and FACS-purified 
from the bone marrow of WT and St2−/− mice for quantitative RT-PCR of chemokine receptors and signals. Data were normalized to a pooled set of three 
housekeeping genes, and differential expression was assessed by the ΔΔCt method. Data are shown as the expression level in St2−/− ILC2Ps compared with 
WT ILC2Ps and are displayed as a log2 fold change. (B) Cxcr4 expression by quantitative RT-PCR in purified ILC2Ps from WT and Il33−/− mice. (c) Purified 
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mice (Fig. 7 K). To test whether this elevated expression of 
CXCR4 was responsible for ILC2P retention in early postna-
tal mice, we treated P15 mice with AMD3100 and evaluated 
the number of ILC2Ps in the bone marrow. Compared with 
vehicle-treated P15 St2−/− mice, AMD3100 treatment signifi-
cantly reduced the number of ILC2Ps in the bone marrow 
(Fig.  7  L). Collectively, these data suggest that endogenous 
IL-33 signaling critically promotes ILC2P egress from the 
bone marrow by attenuating CXCR4 in the early postnatal 
window when ILC2s are robustly seeding tissues.
Allergic airway inflammation induced by the fungal 
allergen Alternaria alternata drives the egress of 
ILc2Ps from the bone marrow
Given that exogenous rIL-33 treatment mobilized ILC2s 
to egress from the bone marrow (Fig. 5), we sought to de-
termine whether exposure to the fungal aeroallergen A. al-
ternata, which induces significant IL-33–dependent allergic 
inflammation, stimulates the egress of ILC2Ps from the bone 
marrow. A. alternata is a fungal species that is associated with 
significant asthma morbidity in humans and drives allergic 
airway inflammation in mice (Salo et al., 2006; Bartemes et 
al., 2012; Doherty et al., 2013; Zhou et al., 2016). We chal-
lenged mice intranasally with Alternaria extract or vehicle 
for four consecutive days and harvested organs 24  h later 
(Fig. 8 A). We identified a significant accumulation of ILC2s 
and their associated cytokine products IL-5 and IL-13 in the 
lungs of Alternaria extract–challenged mice compared with 
vehicle-challenged mice (Fig. S4), consistent with prior re-
search (Bartemes et al., 2012; Doherty et al., 2013; Zhou et 
al., 2016). Intranasal challenge with Alternaria extract signifi-
cantly altered the cellular composition of the bone marrow, 
with a strong trend toward a decrease in total bone marrow 
cell number driven largely by a statistically significant decrease 
in the number of FSC-Alo SSC-Alo cells (Fig. 8, B–D). Among 
these lymphocytes, there was a statistically significant decline 
in the frequency and total number of ILC2Ps in the bone 
marrow of mice challenged with Alternaria extract compared 
with vehicle (Fig.  8, B, E, and F). Concurrently, intranasal 
Alternaria extract challenge stimulated an increase in serum 
IL-33 concentrations compared with vehicle (Fig. 8 G). Al-
ternaria extract challenge induced significant changes in the 
bone marrow cellular composition in an IL-33–indepen-
dent manner, with a significant decrease in FSC-Alo SSC-Alo 
cells in both WT and St2−/− mice (Fig. 8 H). However, IL-
C2P-specific egress required IL-33, with Alternaria extract 
challenge decreasing the number of ILC2Ps in the bone mar-
row of WT but not St2−/− mice (Fig. 8 I). We did not detect 
differences in CXCR4 expression with 4- or 10-d Alternaria 
extract challenge, or with a single 25-µg challenge of Alter-
naria extract (not depicted). These results likely reflect the dy-
namic challenge of capturing a down-regulation of CXCR4 
expression as ILC2Ps exit the bone marrow. They may also 
suggest that IL-33–dependent, non-CXCR4 pathways are 
more critical for regulating ILC2P egress in this aeroaller-
gen model. Beyond ILC2Ps, Alternaria extract challenge in-
creased the total number of eosinophil progenitors, mast cell 
progenitors, and neutrophils while reducing the total number 
of B cells and NK cells in the bone marrow (Fig. S1 G). Col-
lectively, these data demonstrate that allergic airway inflam-
mation promotes egress of ILC2Ps from the bone marrow in 
an IL-33–dependent manner.
tissue disruption and IL-33 promote ILc2 
trafficking and tissue seeding
ILC2s are principally tissue-resident cells in adult, naive mice 
(Gasteiger et al., 2015; O’Sullivan et al., 2016). However, 
prolonged (15-d) infection with the helminth N. brasiliensis 
leads to infiltration of hematogenously sourced ILC2s 
(Gasteiger et al., 2015). Moreover, initial ILC2 accumulation 
in the lungs progresses rapidly within the first 2 wk after 
birth in an IL-33–dependent manner (de Kleer et al., 2016; 
Saluzzo et al., 2017; Steer et al., 2017). Using a parabiosis 
model with sublethal radiation exposure, we sought to 
model tissue disruption and empty niche filling to determine 
whether IL-33 augments hematogenous trafficking of ILC2s. 
First, WT congenic CD45.1+ C57BL/6 mice were left 
nonirradiated or were treated with a sublethal dose (5 Gy) of 
radiation and subjected to parabiosis with naive WT CD45.2+ 
C57BL/6 mice (Fig. 9 A). We performed these surgeries in 
C57BL/6 mice, as we found that parabiosis of BALB/c mice 
caused significant mortality (>60% mortality by 4 wk after 
ILC2Ps from WT mice were treated for 24 h in vitro with IL-2 in combination with varying doses of IL-33 and assessed for CXCR4 expression. (d) Quanti-
fication of C. (e) CXCR4 expression in purified ILC2Ps from WT, Il33−/−, and St2−/− mice that were treated for 24 h in vitro with 1 ng/ml IL-33. For D and 
E, IL-2–treated WT, Il33−/−, and St2−/− samples are normalized to 100%, and IL-33–treated samples are displayed as a percentage of IL-2–treated samples 
within each genotype (WT, Il33−/−, and St2−/−). (F) Mean fluorescence intensity (MFI) of CXCR4 on ILC2Ps and the percentage of ILC2Ps expressing CXCR4 
in adult female mice that were treated intravenously with 4 µg rIL-33 or vehicle and killed 24 h later. (G) WT and St2−/− mice were treated intraperitoneally 
with three doses of AMD3100 (10 mg/kg) or PBS vehicle given every 6 h, and bone marrow was collected for flow cytometric analysis 4 h after the final 
AMD3100 dose. (H) Total number of ILC2Ps in the bone marrow from adult female WT and St2−/− mice treated as in G. (I) MFI of CXCR4 on ILC2Ps, and 
the percentage of ILC2Ps expressing CXCR4 in P2 WT and St2−/− mice. (J) MFI of CXCR4 on ILC2Ps, and the percentage of ILC2Ps expressing CXCR4 in P15 
WT and St2−/− mice. (K) MFI of CXCR4 on ILC2Ps, and the percentage of ILC2Ps expressing CXCR4 in P15 WT and Il33−/− mice. (L) Total number of ILC2Ps 
in the bone marrow of P15 WT and St2−/− mice treated as in G. Data are combined from two (B, n = 6–8; L, n = 7–11) or three (A, n = 12; H, n = 10–11) 
independent experiments or are representative of two (E, n = 3; F, n = 4; I, n = 5; K, n = 5–6) or three (C and D, n = 4; J, n = 4–5) independent experiments 
and displayed as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by one-way ANO VA with Bonferroni posttest (D, H, and L) or unpaired t test (A, B, 
E, F, and I–K); n.s., not significant; N.D., not detected.
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surgery, unpublished observation). Parabiotic mouse pairs 
were housed for 6 wk before tissues were harvested, allowing 
for cells to exchange hematogenously between partners. In 
the spleens of nonirradiated :naive mouse pairs, highly mobile 
populations including CD4+ T cells, CD8+ T cells, and B cells 
were identified in an ∼1:1 ratio, indicating the formation of 
a robust vascular bridge across the parabionts (Fig. 9 B). We 
next assessed for the number of trafficked CD45.2+ ILC2s 
in the tissues from the WT congenic CD45.1+ mice. In the 
nonirradiated mice, we found very few trafficked CD45.2+ 
ILC2s (<5%) in the lungs, skin, or mLNs (Fig. 9, C and D), 
consistent with prior studies (Gasteiger et al., 2015; O’Sullivan 
et al., 2016). However, in the irradiated mice, we found 
significant increases in the percentage of trafficked CD45.2+ 
ILC2s in the lungs, skin, and mLNs (Fig. 9, C and D). Little 
to no trafficking of ILC2s was observed from the CD45.1+ 
parabionts into the CD45.2+ parabionts as expected, with 
radiation exposure in the CD45.1+ mouse further reducing 
basal trafficking of ILC2s to the CD45.2+ mouse, possibly 
because of modest dysfunctions in lymphopoiesis as a result 
Figure 8. Allergic airway inflammation induced by the fungal aeroallergen A. alternata promotes increased serum IL-33 and ILc2P egress from 
the bone marrow. (A) Adult WT mice were treated for four consecutive days with an intranasal challenge of A. alternata extract or PBS vehicle and killed 
24 h after the final treatment. (B) Representative gating for ILC2Ps in the bone marrow. (c) The total number of viable bone marrow cells. (d) The total 
number of FSC-Alo SSC-Alo cells in the bone marrow. (e) ILC2P frequency among live bone marrow cells. (F) The total number of ILC2Ps in the bone marrow. 
(G) The concentration of IL-33 in the serum as measured by ELI SA. (H) The total number of FSC-Alo SSC-Alo cells. (I) ILC2Ps in WT and St2−/− mice treated 
for four consecutive days with Alternaria extract. For H and I, PBS-treated WT and St2−/− mice were normalized to 100%, and Alternaria extract–treated 
mice are displayed as a percentage of PBS-treated within each genotype (WT and St2−/−). Data are combined from two (H and I, n = 7) or three indepen-
dent experiments (C–G, n = 13–15) or representative of three independent experiments (B) and displayed as the mean ± SEM. *, P < 0.05; ***, P < 0.001 by 
unpaired t test (C–G) or one-way ANO VA with Bonferroni posttest (H and I); n.s., not significant. Dashed line in G indicates limit of detection of the assay. 
Values within flow plots indicate percentage of the parent population.
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of sublethal radiation exposure (Fig. 9 E). Collectively, these 
data demonstrate a critical capacity for ILC2s to traffic 
hematogenously to repopulate disrupted tissues.
We next sought to understand how IL-33 shapes the 
ability of ILC2s to traffic and reseed tissues. Sublethally irra-
diated WT CD45.1+ mice were subjected to parabiosis with 
naive WT CD45.2+ mice and rested for 2 wk. Mice were sub-
sequently treated twice weekly with intravenous vehicle or 
rIL-33 (2 µg per parabiotic pair) for four consecutive weeks, 
and organs were harvested to assess for ILC2 trafficking to 
the lungs, skin, and mLNs (Fig. 9 F). rIL-33 treatment pro-
duced a threefold enrichment of trafficked CD45.2+ ILC2s in 
the lungs of CD45.1+ mice compared with vehicle treatment 
(Fig. 9, G and H). However, IL-33 did not significantly affect 
ILC2 migration from the naive mouse to the skin or mLNs 
of the irradiated parabiont in this model. Moreover, CD45.1+ 
ILC2s did not substantially infiltrate the CD45.2+ tissues with 
or without rIL-33 treatment (Fig. 9 I). Thus, IL-33 critically 
enhances ILC2 hematogenous migration and tissue repop-
ulation in a lung-tropic manner. These results demonstrate 
the potential importance of IL-33–associated mechanisms, 
such as promoting bone marrow egress, that mobilize ILC2s 
for hematogenous spread.
dIscussIon
In this study, we evaluated the effect of IL-33 on the devel-
opment and egress of ILC2Ps from the bone marrow. IL-33 
was a critical regulator of ILC2P egress from the bone mar-
row. Mice lacking IL-33 signaling accumulated ILC2Ps in 
the bone marrow significantly more than WT controls, and 
exogenous, intravenous rIL-33 treatment of mice signifi-
cantly reduced the number of ILC2Ps in the bone marrow. 
IL-33–mediated egress was critically important in the perina-
tal period, when ILC2s are rapidly populating tissues. ILC2P 
egress occurred in an ILC2P-intrinsic, IL-33–dependent 
manner, with IL-33 negatively regulating the bone marrow 
retentive chemokine receptor CXCR4. Fungal aeroallergen 
challenge with Alternaria extract promoted ILC2P egress in 
an IL-33–dependent manner. Finally, IL-33 augmented ILC2 
hematogenous trafficking to the lungs in a parabiosis model 
of tissue disruption and repopulation. Collectively, these data 
establish a novel role for IL-33 in promoting the egress of 
ILC2Ps from the bone marrow.
Several prior studies have identified modest to signif-
icant reductions in the number of ILC2s in peripheral tis-
sues of naive or vehicle-treated mice in the absence of IL-33 
signaling, especially in the perinatal period (Bartemes et al., 
2012; Hardman et al., 2013; Li et al., 2014; Brestoff et al., 2015; 
de Kleer et al., 2016; Saluzzo et al., 2017; Steer et al., 2017). 
We had initially hypothesized that this may be caused by a 
developmental impedance, as IL-33 promotes ILC2 differen-
tiation from CLPs in vitro (Wong et al., 2012; Xu et al., 2015). 
Surprisingly, IL-33 appeared dispensable for the development 
of ILC2Ps that are able to proliferate and produce IL-5 and 
IL-13. Further characterization of ILC2 development will be 
necessary to assess whether ILC2 functions beyond prolifer-
ative potential, and IL-5/IL-13 producing capacity may be 
affected by development in an IL-33–deficient environment.
Our data do point to a vital role for IL-33 in promot-
ing efficient egress of ILC2Ps from the bone marrow, at least 
partially via direct signaling on ILC2Ps to negatively regulate 
CXCR4. Our results suggest that this IL-33/CXCR4 effect 
is most pronounced in the perinatal period when ILC2s are 
rapidly seeding tissues, as differences in CXCR4 expression 
and inhibition via AMD3100 were most evident in P15 mice 
compared with adult mice. However, exogenous IL-33 ex-
posure still mobilized ILC2P egress in adult mice. Therefore, 
additional IL-33–dependent pathways may collaborate with 
CXCR4 to promote retention or egress of ILC2Ps, partic-
ularly in adult mice. In neutrophils and hematopoietic stem 
cells, CXCR4 works in conjunction with the integrin VLA-4 
to mediate retention in the bone marrow (Bonig et al., 
2009; Petty et al., 2009). It is intriguing to consider VLA-4/
VCAM-1 as a potential collaborator, but further work will 
be needed to establish a role for integrins in ILC2P bone 
marrow retention. In addition, in vivo CXCR4 inhibition 
with AMD3100 is not specific to ILC2Ps, and therefore we 
cannot at the present time definitively exclude an indirect 
mechanism of action for CXCR4 blockade in promoting 
ILC2P bone marrow egress. Warts, hypogammaglobulinemia, 
immunodeficiency, and myelokathexis (WHIM) syndrome is 
a rare autosomal dominant disorder in which mutations in 
CXCR4 lead to hyperactive or prolonged signaling through 
this receptor (Kawai and Malech, 2009). Patients with WHIM 
syndrome present with recurrent infections, hypogamma-
globulinemia, and retention of neutrophils in the bone mar-
row. WHIM syndrome may represent a clinical scenario in 
which we can better understand the role of CXCR4 signal-
ing in human ILC2 biology.
The extent and timing of ILC trafficking remains an 
area of ongoing investigation. Early work performed in 
naive, adult parabiotic mice demonstrated that in the un-
challenged setting, ILCs including ILC2s are predominantly 
tissue resident (Gasteiger et al., 2015; O’Sullivan et al., 
2016). However, protracted type 2 inflammation associated 
with N. brasiliensis infection induced moderate infiltration 
of ILC2s but not ILC1s or ILC3s to the sites of inflamma-
tion (Gasteiger et al., 2015). Short-term intranasal delivery 
of IL-33 did not elicit significant ILC2 trafficking to the 
lungs in parabiotic mice (Moro et al., 2016), but extended 
allergen exposure correlated with increased ILC2s in the 
blood and accumulation of ILC2s in the lungs in a β2 in-
tegrin–dependent manner that was independent of prolif-
eration or apoptosis, suggestive of trafficking (Karta et al., 
2017). Further evidence for trafficking of ILCs was obtained 
using the Kaede transgenic mouse model in which inducible 
photoconverted ILCs were tracked from the intestinal tissue 
to draining lymph nodes in significant quantities (Mackley 
et al., 2015). Several important differences in the design of 
these experiments may explain the divergent results. Specif-
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Figure 9. IL-33 and tissue disruption promote ILc2 trafficking for tissue repopulation. (A) Experimental design for B–E: C57BL/6 congenic CD45.1+ 
WT mice were either irradiated with 5 Gy or not irradiated, and were subjected to parabiosis with naive C57BL/6 CD45.2+ WT mice for 6 wk. (B) Percentage 
of donor CD4+ T, CD8+ T, and B cells in recipient tissues from nonirradiated mouse pairs. (c) Representative flow plots. (d) Quantification of the frequency of 
CD45.2+ ILC2s collected from the lung, skin, and mLNs of the CD45.1+ parabiont (irradiated or nonirradiated). (e) Quantification of the frequency of CD45.1+ 
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ically, the length of the tissue disruption, the strength of the 
tissue inflammatory stimulus, and the quality of the associ-
ated inflammation (type 1 vs. type 2) are all likely factors in 
influencing the degree of ILC2 trafficking. Together, these 
data suggest that although ILC2s are primarily tissue resi-
dent, reseeding may occur in the appropriate inflammatory 
setting such as infection and allergen challenge.
In our study, we used a parabiotic model of radia-
tion-induced tissue disruption to create an empty-niche ef-
fect. Our principal aim was to study ILC2 trafficking during 
the population of tissues, with implications for initial ILC2 
seeding of tissues during development and the repopulation 
of ILC2s after substantial tissue disruption. Our data demon-
strate that radiation-induced tissue disruption elicited marked 
reseeding of the lungs, skin, and mLNs by hematogenously 
sourced ILC2s. Moreover, intravenous IL-33 treatment sig-
nificantly increased ILC2 trafficking to the lungs in this 
model. Radiation induced a similar tissue-migratory effect in 
human severe combined immunodeficiency patients receiv-
ing hematopoietic stem cell transplants for tissue reseeding 
with donor ILC2s (Vély et al., 2016). Together, our data in 
conjunction with published research support a participatory 
role for ILC2 trafficking, augmented by IL-33, during ini-
tial tissue seeding and in settings of repopulation after de-
pletion of resident ILC2s.
Increased plasma concentrations of IL-33 have been 
observed in numerous human diseases including asthma 
(Bonanno et al., 2014; Bahrami Mahneh et al., 2015; Chau-
han et al., 2015), atopic dermatitis (Tamagawa-Mineoka et 
al., 2014), allergic rhinitis (Glück et al., 2012), inflammatory 
bowel disease (Pastorelli et al., 2010; Saadah et al., 2015), 
rheumatoid arthritis (Matsuyama et al., 2010; Mu et al., 
2010), and psoriasis (Mitsui et al., 2016), among others. In 
many of these diseases, ILC2s are thought to participate in 
driving inflammation. Our data in mice demonstrate that 
the intravenous delivery of rIL-33 mobilizes ILC2Ps to 
egress from the bone marrow. Moreover, fungal aeroallergen 
challenge in mice promoted the exit of ILC2Ps from the 
bone marrow in an IL-33–dependent manner. It is inter-
esting to consider whether a similar effect exists in humans, 
and whether anti-IL-33 therapeutics currently in devel-
opment may reduce inflammation by not only blocking 
local tissue effects but also reducing the recruitment of new 
ILC2s. Although some evidence suggests that ILC2s may 
traffic with strong, protracted type 2 inflammatory stimuli 
(Gasteiger et al., 2015; Karta et al., 2017), further studies will 
be necessary to understand the possible migration of ILC2s 
during allergic inflammation, as our trafficking studies pri-
marily focused on a model of empty niche filling rather 
than allergic inflammation.
IL-33 regulated the expression of multiple chemo-
kine receptors in ILC2Ps. Specifically, IL-33 decreased 
the expression of Cx3cr1, Ccr7, Ccr9, Cxcr4, and Ptgdr2 
and increased the expression of Ccl1. Notably, CCR9 is 
a gut-tropic signaling pathway (Griffith et al., 2014), and 
IL-33 may be skewing ILC2 migration toward sites outside 
of the gastrointestinal tract. Within the gastrointestinal tract, 
tuft cell–derived IL-25 is thought to be a key regulator of 
ILC2 responsiveness (Howitt et al., 2016; von Moltke et al., 
2016). Tuft cells are not major sources of IL-33, and any 
trafficking bias induced by IL-33 may function to guide cells 
to areas of higher IL-33 content. rIL-33 treatment prefer-
entially guided ILC2s to the lungs in our parabiosis model, 
consistent with this hypothesis.
Given the effect of IL-33 on regulating chemokine 
receptor expression in bone marrow ILC2Ps, it is plausible 
that IL-33 may also shape the chemokine receptor profiles 
of peripheral ILC2s. Beyond retention of cells in the bone 
marrow, CXCR4 is involved in several biological processes 
including the trafficking of lymphocytes into secondary 
lymphoid organs (Griffith et al., 2014). ILC2s readily cycle 
between tissues and adjacent lymph nodes (Mackley et al., 
2015) and also interface with the adaptive immune system 
(Moro et al., 2010; Drake et al., 2014, 2016; Gold et al., 2014; 
Halim et al., 2014, 2016; Mirchandani et al., 2014; Oliph-
ant et al., 2014). Whether peripherally expressed IL-33 affects 
ILC2 trafficking between tissues and secondary lymphoid 
organs in a CXCR4-dependent manner remains unknown. 
IL-33 may also work in combination with other signals to 
exert tissue-specific effects on ILC2 chemokine receptor ex-
pression, and additional characterization will be needed on a 
tissue-by-tissue basis.
Herein, our data provide evidence that IL-33 promotes 
the egress of ILC2Ps from the bone marrow. Mice lacking 
IL-33 signaling had a significant accumulation of ILC2Ps in 
the bone marrow, including during the critical perinatal pe-
riod associated with ILC2 accumulation in tissues, that was 
mechanistically driven by an overexpression of CXCR4. 
Intravenously delivered IL-33 and fungal allergen challenge 
rapidly and significantly mobilized ILC2Ps to egress from the 
bone marrow. These data broadly expand our understanding 
of IL-33 biology and ILC2 migration.
ILC2s collected from the lung, skin, and mLNs of the CD45.2+ parabiont. (F) Experimental design for G–I: C57BL/6 congenic CD45.1+ WT mice were irradiated 
with 5 Gy and subjected to parabiosis with naive C57BL/6 CD45.2+ WT mice. 2 wk after surgery, mouse pairs were treated intravenously twice weekly with 
vehicle (0.1% BSA in PBS) or 2 µg rIL-33 for four consecutive weeks. (G) Representative flow plots. (H) Quantification of the frequency of CD45.2+ ILC2s 
collected from the lung, skin, and mLNs of the CD45.1+ parabiont. (I) Quantification of the frequency of CD45.1+ ILC2s collected from the lung, skin, and 
mLNs of the CD45.2+ parabiont. Data are combined from two (B, n = 14; D and E, n = 7–8; H and I, n = 3–4) independent experiments or representative of 
two (C and G) independent experiments and displayed as the mean ± SEM. **, P < 0.01; ***, P < 0.001 by unpaired t test. Values within flow plots indicate 
percentage of the parent population.
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Mice
Female 8–12-wk-old Il33−/−, St2−/−, and Tslpr−/− mice on a 
BALB/c genetic background were used throughout this arti-
cle, unless otherwise indicated, and were generated as previ-
ously described (Townsend et al., 2000; Carpino et al., 2004; 
Zhou et al., 2005; Hardman et al., 2013). WT BALB/c mice 
were obtained from the Jackson Laboratory and used as con-
trols. In some experiments, BALB/c congenic CD45.1+ WT 
(CByJ.SJL(B6)-Ptprca/J) mice were obtained from the Jack-
son Laboratory and used as controls. Where indicated, exper-
iments were performed with C57BL/6 mice. C57BL/6 WT 
and C57BL/6 congenic CD45.1+ WT (B6.SJL-PtprcaPepcb/
BoyJ) mice were obtained from the Jackson Laboratory, and 
Il33−/− mice on a C57BL/6 background were generated 
as previously described (Oboki et al., 2010). Heterozygous 
BALB/c CD45.1+ CD45.2+ WT mice were generated from 
crossing BALB/c mice with CByJ.SJL(B6)-Ptprca/J mice. 
Age-matched pups were obtained from timed breeding of 
BALB/c WT, Il33−/−, and St2−/− mice. All animals were used 
in compliance with the revised 1996 Guide for the Care 
and Use of Laboratory Animals prepared by the Committee 
on Care and Use of Laboratory Animals of the Institute of 
Laboratory Animal Resources, National Research Council. 
All animal experiments were approved by the Vanderbilt In-
stitutional Animal Care and Use Committee. Animals were 
housed under specific pathogen–free conditions. Animals 
were anesthetized with ketamine/xylazine and killed with 
pentobarbital overdose.
Flow cytometry
Bone marrow was isolated by flushing the tibia and femur 
with cold RPMI medium. For mLNs and spleen, tissue was 
grated through a 70-µm strainer into cold RPMI medium. 
The external portions of the left and right ears were collected 
for evaluation of skin ILC2s. For the disruption of the lungs 
and skin, tissue was mechanically minced and digested with 
1 mg/ml collagenase (C5138; Sigma-Aldrich) and 0.02 mg/
ml DNase I (D4527; Sigma-Aldrich) in RPMI with 5% FBS 
for 55 min at 37°C as previously described (Stier et al., 2016). 
EDTA was added to quench the enzymatic reaction, and the 
tissue was filtered through a 70-µm strainer. RBC lysis was 
performed, and all samples were counted with Trypan blue 
exclusion to assess total numbers of cells within each tissue. 
Three to five million cells were stained for flow cytometry 
in FACS buffer (PBS + 3% FBS). Cells were initially blocked 
with a 1:25 dilution of anti-CD16/CD32 blocking reagent 
(553142; BD Biosciences) and were subsequently stained for 
combinations of the surface markers listed in Table S1. Via-
bility dye (DAPI or PI) was added immediately before flow 
cytometric analysis. Samples were measured on a BD LSR 
II and analyzed with FlowJo version X. Doublets were re-
moved based on forward/side scatter properties, and dead 
cells were excluded in all analyses as PI+ or DAPI+. ILC2s 
and ILC2Ps were defined as CD45+ Lin− IL-25R+ CD25+ 
CD127+, where Lin represents a lineage cocktail containing 
antibodies against CD3, CD5, CD45R (B220), CD11b, Gr-1 
(Ly-6G/C), 7-4, and Ter-119. ILC2s and ILC2Ps defined by 
this gating strategy coexpressed validated phenotypic markers 
found on ILC2s in a variety of tissues in WT mice including 
CD90, ST2, and ICOS, although ST2 expression was not ob-
served in the skin (Fig. S5). In some experiments, cells were 
stained for donor source using anti-CD45.1 or anti-CD45.2 
(Table S1). Full gating strategies for all cell types assessed 
throughout the article are listed in Table S3.
In vitro ILc2P culture
Bone marrow was prepared as described in Flow cytometry. 
After RBC lysis, samples were enriched for Lin-negative cells 
by magnetic separation per manufacturer instructions (130-
110-470; Miltenyi Biotec). Enriched cell fractions were pre-
pared for FACS, and ILC2Ps were sorted on a BD FAC SAria 
III into RPMI with 10% FBS, 2  mM l-glutamine, 1  mM 
sodium pyruvate, 10 mM Hepes, and 100 units/ml penicillin 
and streptomycin. In some assays, ILC2Ps were stained before 
culture with the dilution-based proliferation dye CellTrace 
Violet per manufacturer instructions (C34557; Life Tech-
nologies). ILC2Ps were plated at 2,500 cells/well in 96-well 
round-bottom plates. ILC2Ps were cultured with IL-2 (10 
ng/ml, 212-12; PeproTech) alone or in combination with 
IL-33 (0.1–10 ng/ml, 210-33; PeproTech) for 1–5 d.
Protein measurements
Cell culture supernatants from in vitro ILC2P cultures were 
collected for the measurement of IL-5 and IL-13 by ELI SA 
(DY405 and DY413; R&D Systems) per manufacturer instruc-
tions. Serum IL-33 protein levels were measured by ELI SA 
(M3300; R&D Systems) per manufacturer instructions.
Brdu assay
Mice were treated in vivo with 1 mg BrdU intraperitone-
ally either once and killed 2  h later or once daily for five 
consecutive days and killed 24  h later. Bone marrow was 
harvested 24 h after the final treatment, and cells were pre-
pared for flow cytometric analysis per manufacturer instruc-
tions (552598; BD Biosciences). In brief, cells were stained 
with a fixable live/dead viability dye (13-0868; Tonbo Bio-
sciences) followed by anti-CD16/CD32 blockade and anti-
bodies against ILC2P cell-surface markers (Table S1). Cells 
were fixed and permeabilized, and the DNA was treated with 
DNase I for 1 h at 37°C to expose BrdU epitopes. Cells were 
subsequently stained with an anti-BrdU antibody and mea-
sured by flow cytometry to assess the total number of BrdU+ 
ILC2Ps in the bone marrow.
Bone marrow chimeras
6- to 10-wk-old heterozygous CD45.1+ CD45.2+ WT 
BALB/c recipients were lethally irradiated (9 Gy) and trans-
planted with a 1:1 mixture of whole bone marrow from age-
matched 6- to 10-wk-old BALB/c WT congenic (CD45.1+) 
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and St2−/− (CD45.2+) mice via retroorbital injection while 
anesthetized with ketamine/xylazine. Mice were provided 
with sulfamethoxazole/trimethoprim in the drinking water 
for 2 wk after transplant and were maintained in sterile hous-
ing. Bone marrow grafts were allowed to reconstitute for 6 
wk. Mice were subsequently killed to collect bone marrow, 
lungs, skin, and mLNs to assess donor frequencies by flow 
cytometry. Residual cells remaining from the recipient mice 
(CD45.1+ CD45.2+) were excluded.
mrnA quantification
ILC2Ps from WT, Il33−/−, and St2−/− mice were enriched 
for Lin-negative cells by magnetic separation and puri-
fied by FACS as described in Flow cytometry. Cells were 
sorted into cold PBS and centrifuged at 10,000  g for 5 
min to remove the supernatant. mRNA was collected from 
the pelleted ILC2Ps using the RNeasy Micro kit (74004; 
QIA GEN) with on-column DNase treatment. cDNA 
was prepared using the SuperScript IV reverse transcrip-
tion system (18091050; Invitrogen). Because of low cell 
input (fewer than 20,000 sorted ILC2Ps per sample), we 
performed a preamplification for our target genes as per 
manufacturer instructions (4384267; Applied Biosystems). 
A conventional quantitative PCR using the preamplifica-
tion product and FAM-MGB TaqMan primers listed in 
Table S2 was performed on an Applied Biosystems Quant-
Studio12k Flex Real-Time PCR machine, and data were 
analyzed using Applied Biosystems QuantStudio 12k Flex 
Software v.1.2.2. Six candidate housekeeping genes were 
evaluated for stable expression in ILC2Ps as previously de-
scribed (Vandesompele et al., 2002), and target genes were 
normalized to the geometric mean Ct values of a pool 
of three of these stably expressed reference genes: Rpl13a, 
Ywhaz, and Hprt. Differential expression was assessed by 
using the ΔΔCt protocol.
In vivo AMd3100 and IL-33 treatments
For CXCR4 blockade, mice were treated with intraperi-
toneal injections of 10 mg/kg AMD3100 (A5602; Sig-
ma-Aldrich) or vehicle PBS every 6 h for a total of three 
consecutive doses. Mice were killed 4  h after the final 
dose of AMD3100. For IL-33 treatments, mice were anes-
thetized with ketamine/xylazine and treated with 0.25, 
1, or 4 µg rIL-33 (210-33; PeproTech) or vehicle (0.1% 
BSA in PBS) via retroorbital injection. Mice were killed 
24 h after IL-33 injection.
In vivo challenge with A. alternata extract
WT and St2−/− mice were anesthetized with ketamine/xyla-
zine and challenged intranasally with either 5 µg A. alternata 
extract (Greer) dissolved in 100 µl PBS or 100 µl PBS (ve-
hicle) every 24 h for four consecutive days. Mice were killed 
24  h after the final dose of Alternaria extract, and serum, 
lungs, and bone marrow were collected for analysis.
Parabiosis
C57BL/6 congenic CD45.1+ WT mice were left untreated 
or were sublethally irradiated (5 Gy) and parabiosed to 
C57BL/6 CD45.2+ WT mice. Mice were anesthetized with 
ketamine/xylazine and partially shaved to expose the surgical 
site. Surgical sites were sterilized with betadine and alcohol, 
and lateral incisions were made in the skin between the knee 
joint and the elbow joint. Sutures were placed connecting 
the knee and elbow joints of the two mice for anchoring. 
Skin was aligned between the two mice and sutured from one 
mouse to the other to close the incision site. Buprenorphine 
was administered for analgesia for the first 48 h after surgery. 
Wet food, dry food, and water were provided on the floor of 
the cage. As needed, mice were supplemented with physio-
logical saline to prevent dehydration. In some experiments, 
starting on day 14 after surgery, mouse pairs were treated with 
vehicle (0.1% BSA in PBS) or rIL-33 (2 µg) twice weekly via 
retroorbital injection into the right eye of the CD45.2+ WT 
mouse for four consecutive weeks.
statistics
Statistical analyses were performed using GraphPad Prism 
v.5. Unpaired t test or one-way ANO VA with Bonferroni 
post-test were used to determine statistical significance, as 
appropriate. When measured values were below the limit of 
detection, samples were assigned a value at half of the limit of 
detection to allow for statistical comparisons.
online supplemental material
Fig. S1 shows cell quantification, CCR3, or CXCR4 expres-
sion for major cell lineages in the bone marrow of St2−/−, 
rIL-33–treated, and Alternaria extract–treated mice. Fig. S2 
shows the frequency and total number of ILC2Ps in the 
bone marrow and ILC2s in the lungs of Tslpr−/− mice. Fig. 
S3 shows flow cytometry gating strategies for LMPPs, CLPs, 
CHI LPs, and ILCPs. Fig. S4 shows the number of ILC2s 
and the quantification of their cytokine products IL-5 and 
IL-13 in the lungs of Alternaria extract–treated mice. Fig. S5 
shows the surface expression of CD90, ST2, and ICOS on 
ILC2Ps/ILC2s in the bone marrow, lungs, skin, and mLNs. 
Table S1 lists flow cytometry and FACS antibodies. Table 
S2 lists quantitative PCR primers. Table S3 lists flow cy-
tometry gating strategies.
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